Zepzelca, in combination with Roche's Tecentriq, is the first approved first-line maintenance therapy for extensive-stage small cell lung cancer.
ProSense cryoablation system gains marketing authorization as the first minimally invasive treatment for low-risk tumors in women over 70.
Regulators expedite review for ALTO-101, a novel treatment for cognitive impairment in schizophrenia, a condition with no currently approved therapies.
The newly formed company, which began trading on Nasdaq this week, faces intense volatility following the finalized deal and ahead of a planned reverse stock split.
Government award will advance the company's non-vaccine influenza therapeutic, CD388, and onshore its manufacturing ahead of a potential pandemic.
The communications technology firm has completed its merger with Core Gaming and will relaunch on October 7th as an artificial intelligence holding company.
Regulators expedite review for ALTO-101, targeting a key aspect of schizophrenia with no currently approved treatments.
The sale of the controlling interest in the insurance platform represents a significant and rapid return on investment for White Mountains.